Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc. > UTA Voices Podcast Episode with Dr. McFarland now available
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1117)
•••
Comment by Pandoraon Apr 19, 2022 10:58pm
357 Views
Post# 34615346

RE:RE:UTA Voices Podcast Episode with Dr. McFarland now available

RE:RE:UTA Voices Podcast Episode with Dr. McFarland now availableThey didn't ask me but if they did I might have suggested using a different word than "hopefully". Oh well, sounds good anyway to get the message out to another audience.

gebremeskel wrote: "...The procedure starts with instillation of the drug directly into the bladder. And the patients wait for about an hour for the tumours to soak up the drug. And then once that period has elapsed then we bring in green light through fibre optics right into the bladder - illuminate for - the time depends on the individual patient's bladder size, scarring and those sorts of things. But it could be up to an hour. And then hopefully after one treatment the tumours are eradicated. In this particular clinical trial we're doing two treatments 180 days apart just to be on the safe side...but so far so good..."

Eoganacht wrote:
48 minute talk taped earlier today:

Voices Live :: Talking Chemistry with UTA's Frank Foss and Sherri McFarland

https://anchor.fm/utascience/episodes/Voices-Live--Talking-Chemistry-with-UTAs-Frank-Foss-and-Sherri-McFarland-e1hdfip
 



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities